• Chronic Cabozantinib Exposure Remodels RCC Phosphoproteome

  2026-06-08

  This study employs quantitative phosphoproteomics to map how renal cell carcinoma (RCC) cells adapt to acute versus chronic Cabozantinib (XL184) exposure, revealing distinct, timescale-dependent remodeling of phosphorylation networks. The findings clarify how chronic drug pressure sustains MET inhibition yet selectively rewires cell adhesion and motility pathways, informing future RCC model design and antiangiogenic research.

• Crizotinib Hydrochloride: Transforming Tumor-Stroma Research

  2026-06-08

  Explore how Crizotinib hydrochloride, a leading ALK kinase inhibitor, advances the study of tumor–stroma interactions in complex cancer models. This article delivers unique insights into its mechanistic utility and integration with patient-derived assembloids, setting new standards for translational cancer biology research.

• USP42 Drives Breast Cancer Progression by Blocking JNK/p38 A

  2026-06-07

  This study establishes USP42 as a key promoter of breast cancer progression through suppression of JNK/p38-mediated apoptosis. The findings clarify USP42’s mechanistic role and highlight its potential as a therapeutic target, with broad implications for molecular oncology workflows.

• Bafilomycin A1: Precision V-ATPase Inhibitor for Cell Biolog

  2026-06-06

  Bafilomycin A1 empowers researchers to selectively and reversibly inhibit V-ATPases, unlocking advanced control over intracellular pH and lysosomal function in diverse cell models. Explore protocol enhancements, troubleshooting strategies, and new cross-domain applications fueled by rigorous reference studies and APExBIO’s trusted supply.

• Advances in Plant Protein Secretion: Protocols and Insights

  2026-06-05

  This Methods in Molecular Biology volume presents refined, step-by-step protocols for the study of protein secretion in plant cells, emphasizing both conventional and unconventional pathways. The collection enables reproducible research by detailing experimental design, materials, and troubleshooting, supporting advances in plant cell biology and comparative studies with yeast and animal systems.

• Cabozantinib (XL184): Systems Pharmacology and Chronic Adapt

  2026-06-05

  Explore how Cabozantinib (XL184) reshapes phosphorylation networks in renal cell carcinoma research. This in-depth article uniquely focuses on timescale-dependent adaptation and its practical impact on experimental design.

• Caspase 3/7 Promote Autophagy and DNA Repair in Breast Cance

  2026-06-04

  The referenced study reveals that caspase 3 and caspase 7 foster cytoprotective autophagy and the DNA damage response in human breast cancer cells under non-lethal stress. This work uncovers non-apoptotic roles for these caspases, broadening our understanding of cellular stress adaptation and highlighting new research and therapeutic directions.

• Medroxyprogesterone Acetate (MPA): Scenario-Driven Lab Solut

  2026-06-04

  This article addresses real laboratory challenges in cell viability, proliferation, and hormone signaling research, focusing on Medroxyprogesterone acetate (SKU B1510). Through scenario-driven Q&A, it guides biomedical scientists in optimizing protocols, data interpretation, and reagent selection, highlighting APExBIO’s reliable MPA for reproducible results.

• Coumestrol: Advanced Phytoestrogen Estrogen Receptor Antagon

  2026-06-03

  Coumestrol’s dual role as a selective estrogen receptor modulator and ferroptosis inducer offers powerful new tools for rheumatoid arthritis research. This guide translates recent mechanistic breakthroughs into practical, optimized workflows for nuclear receptor signaling and inflammation studies.

• Recombinant Human Growth Hormone: Mechanisms & Next-Gen Stra

  2026-06-03

  This thought-leadership article bridges mechanistic discoveries in somatotropin signaling—specifically the IGFBP2-THBS1-IGF-1 axis—with actionable guidance for translational researchers. By integrating the latest evidence on Recombinant Human Growth Hormone (GH) from APExBIO and anchoring discussion in recent peer-reviewed breakthroughs, the piece delivers a roadmap for leveraging high-purity recombinant GH in advanced cellular and bone growth models, protocol optimization, and biomarker-driven research.

• KR-12 Peptide–Cu(II) Interactions: Quantum Chemical Insights

  2026-06-02

  This study applies modern quantum chemical and biophysical methods to elucidate how the KR-12 human antimicrobial peptide, a minimal LL-37 fragment, interacts with copper(II) ions. The findings clarify the structural determinants of peptide–metal binding, deepening understanding relevant for antimicrobial and immunomodulatory research.

• Optimizing PI 3-Kinase Activation: 740 Y-P in Cell Signaling

  2026-06-02

  740 Y-P stands out as a potent, cell-permeable PI 3-kinase activator, enabling precise modulation of the PI3K/AKT pathway for advanced apoptosis, vesicular trafficking, and neuronal survival assays. This article demystifies its workflow integration, experimental troubleshooting, and actionable protocol improvements for high-confidence outcomes in cancer and regenerative medicine.

• Targeted SPP1 Inhibition in Tumor Macrophages Reduces Tumor

  2026-06-01

  This study presents a phenotypic screening approach to identify small molecule modulators capable of down-regulating SPP1 expression in tumor-associated macrophages (TAMs), culminating in the development of a TAM-targeted nanoformulation that effectively reduces tumor size in murine models. The findings offer a promising therapeutic direction for modulating the tumor microenvironment by reprogramming immunosuppressive myeloid cells.

• TRIM26 Drives PRV Infection via NDP52-Mediated MAVS Degradat

  2026-06-01

  This study uncovers how TRIM26, a tripartite motif protein, facilitates pseudorabies virus (PRV) infection by promoting selective autophagic degradation of MAVS through NDP52. The findings provide mechanistic insight into PRV's evasion of innate antiviral responses, with implications for antiviral research and immune modulation strategies.

• NHE1 Drives Octanal/Olfr2-Induced Atherosclerosis via Inflam

  2026-05-31

  This study delineates how NHE1 in macrophages functions as a pivotal mediator in octanal/Olfr2-induced atherosclerosis, orchestrating calcium-dependent ROS generation and NLRP3 inflammasome activation. The findings provide mechanistic insight into macrophage-driven plaque inflammation, highlighting NHE1 as a potential therapeutic target in vascular disease.

15367 records 1/1025 page Next 12345 下5页 Last page